Opendata, web and dolomites

InterTAU SIGNED

Integrative structural biology of pathological tau protein, an appealing therapeutic target for Alzheimer´s disease modifying drugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 InterTAU project word cloud

Explore the words cloud of the InterTAU project. It provides you a very rough idea of what is the project "InterTAU" about.

assembled    cellular    disease    academic    solid    resonance    outcome    biotech    variants    assays    platform    sharing    efficient    there    diagnosis    innovation    cutting    altered    nuclear    molecular    stage    tauopathies    ing    complementary    relates    microscopy    ad    bioinformatics    oligomerization    cryo    pathology    company    america    inducers    therapy    enormous    toxicity    tau    functional    forms    structural    edge    conformational    sustainable    pursuing    transfer    nmr    unmet    mutual    course    translated    cooperation    pharma    biotechnological    conformationally    magnetic    pathological    expertise    prevention    protein    hampered    envisaged    medical    monomeric    suitable    denominator    deeper    modifying    oligomeric    therapies    lacking    electron    anti    pharmacological    foundation    north    fibrillar    solution    pathogenesis    intertau    alzheimer    characterization    argentina    corroborated    biophysical    immunotherapy    transferred    clinical    assembly   

Project "InterTAU" data sheet

The following table provides information about the project.

Coordinator
Masarykova univerzita 

Organization address
address: Zerotinovo namesti 9
city: BRNO STRED
postcode: 60177
website: http://www.muni.cz

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Czech Republic [CZ]
 Total cost 1˙062˙600 €
 EC max contribution 1˙058˙000 € (100%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2019
 Funding Scheme MSCA-RISE
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Masarykova univerzita CZ (BRNO STRED) coordinator 441˙600.00
2    AXON NEUROSCIENCE R&D SERVICES SE SK (BRATISLAVA) participant 464˙600.00
3    LATVIJAS ORGANISKAS SINTEZES INSTITUTS LV (RIGA) participant 128˙800.00
4    ROYAL COLLEGE OF SURGEONS IN IRELAND IE (DUBLIN) participant 23˙000.00
5    OREGON STATE UNIVERSITY US (CORVALLIS) partner 0.00
6    UNIVERSIDAD NACIONAL DE CUYO AR (MENDOZA) partner 0.00
7    UNIVERSITY HEALTH NETWORK CA (TORONTO) partner 0.00
8    UNIVERSITY OF PITTSBURGH US (PITTSBURGH) partner 0.00

Map

 Project objective

There is an enormous and unmet medical need to find efficient methods of prevention, diagnosis and disease-modifying therapies for tauopathies, including Alzheimer’s disease. The common molecular denominator of tauopathies are pathological forms of tau protein. Tau pathology relates to conformational changes during oligomerization and assembly resulting in toxicity. Given its role in the pathogenesis, conformationally altered and assembled tau would be a promising molecular target for disease-modifying therapy. However, the field is still lacking a deeper understanding of tau structural changes in the course of assembly and their inducers on the pathway towards the pathological forms of Tau; therefore, the pharma development is hampered. The main aim of the InterTau project is the detailed structural and biophysical characterization of tau protein and its variants in monomeric, oligomeric and fibrillar states relevant for AD and other tauopathies. The InterTAU consortium is composed of a clinical-stage biotech company pursuing development of anti-tau immunotherapy and academic partners with cutting-edge methodologies suitable for functional and structural characterization of the tau assembly pathway by solution and solid-state nuclear magnetic resonance (NMR), cryo-electron microscopy and cellular assays corroborated by bioinformatics. The mutual transfer of complementary expertise envisaged in the project will facilitate academic outcome and biotechnological development. Specific expertise will be transferred from three institutions in North America and one institution from Argentina. The results of InterTAU will be directly translated into innovation in pharmacological development through the non-academic partner. The platform for sharing knowledge will be a foundation of sustainable cooperation beyond the InterTau project.

 Deliverables

List of deliverables.
Project website Websites, patent fillings, videos etc. 2020-04-03 12:46:44

Take a look to the deliverables list in detail:  detailed list of InterTAU deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INTERTAU" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INTERTAU" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

ENDORSE (2018)

Safe, Efficient and Integrated Indoor Robotic Fleet for Logistic Applications in Healthcare and Commercial Spaces

Read More  

VIDEC (2020)

Visualizing Death Inducing Protein Complexes

Read More  

TREND (2019)

Transition with Resilience for Evolutionary Development

Read More